NYSE-Listed Bausch Health Calls Its 8.500% 2027 Notes

A redemption notice is one of the quieter documents in corporate finance. It rarely moves headlines, yet it tells bondholders exactly when and how a company intends to close a chapter of its balance sheet. On Wednesday, Bausch Health Companies Inc., which trades on the NYSE and the Toronto Stock Exchange under the ticker BHC, said it is about to send one.

Key takeaways

• Bausch Health announced on Oct. 28, 2026 that it will fully redeem its 8.500% senior notes due 2027.
• The issuer, subsidiary Bausch Health Americas, Inc., will deliver an irrevocable notice of redemption dated Oct. 29, 2026.
• The company is dual-listed, with its shares quoted on the NYSE and the TSX under the same symbol.
• This is a debt-management step, not a change to any exchange listing rules.

What was announced

According to the company’s release, Bausch Health Americas will issue a notice of redemption dated October 29, 2026, covering the 8.500% senior notes that mature in 2027. The word “irrevocable” matters: once the notice is delivered, the issuer is committed to the redemption and cannot withdraw it. The release describes the redemption as full, meaning the entire outstanding balance of that series is to be retired rather than a portion of it.

Bausch Health made the announcement through its Laval, Quebec headquarters. Redemption mechanics for notes of this kind, including dates and prices, are typically set out in the notice and the governing indenture, and holders should look to those documents for specifics.

Why an NYSE listing is relevant here

The notes themselves are debt securities and are separate from the company’s listed equity. Still, issuers whose shares trade on the NYSE operate under continuing-listing frameworks that look at the health of the company as a whole, including its financial condition and disclosure practices. Debt maturities and refinancing plans feed into how investors and analysts assess that picture, which is why redemptions of near-dated notes draw attention.

Nothing in the announcement points to a change in Bausch Health’s listing status on either exchange. The company’s shares continue to trade on the NYSE and the TSX.

A full call of a bond with a 2027 maturity is a reminder that listing status and debt management are separate tracks, but they converge in how the market reads a company’s balance sheet.

Who is affected

Holders of the 8.500% notes are the most directly affected, since their securities are slated to be retired under the notice. Shareholders of Bausch Health may watch how the redemption is funded and what it means for the company’s remaining debt obligations, although those details are not part of the announcement summarized here.

What to watch next

• The redemption date and price stated in the formal notice delivered on Oct. 29.
• Any follow-up regulatory filings from Bausch Health describing the funding source and the effect on its debt schedule.
• Whether the company discusses the redemption in its next earnings commentary.

For readers tracking exchange news, the item is a useful data point on how large NYSE- and TSX-listed issuers manage maturities ahead of their due dates, rather than a signal of any shift in listing standards.